




**WORLD CONGRESS
OF INTERNAL MEDICINE**

**THE
37TH
WCIM 2024
PRAGUE
CZECH REPUBLIC**

30. 10. – 2. 11. 2024

THE CAPITAL CITY OF INTERNAL MEDICINE





MONOCYTE DISTRIBUTION WIDTH (MDW) SEVERITY OF INFECTION MARKER INCORPORATE MDW IN YOUR TRIAGE PROTOCOL IN THE EMERGENCY DEPARTMENT

MDW is proprietary, regulatory cleared hematological biomarker exclusive to Beckman Coulter analyzers that helps to identify severity of infection and risk of sepsis in adult patients in ED¹

MDW helps reduce Dx uncertainty, aiding clinicians in escalating or de-escalating care in patients with suspected infectious etiology

MDW is available early in patient assessment as a part of a CBC with Differential test on the DxH 900 or DxH 690T hematology analyzers using the Early Sepsis Indicator (ESId) application, no impact to workflow

Learn how to incorporate MDW in your emergency department sepsis assessment protocol at beckmancoulter.com/solutions/detect-sepsis-earlier

1. Intended use in conjunction with appropriate laboratory tests and clinical signs and symptoms.



© 2022 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. For Beckman Coulter's worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact

2024_HGM2022-321 | 2022-10946-Heme Sepsis_A5_imprint-HEM-Other-CZ-EN

CONTENTS

WELCOME MESSAGE

COMMITTEES

PROGRAMME OVERVIEW

DETAILED PROGRAMME

USEFUL INFORMATION

PARTNERS AND EXHIBITORS

EXHIBITION PLAN

INDUSTRY SYMPOSIA

FLOORPLANS

WELCOME MESSAGE

Dear colleagues, dear friends,

Allow me to welcome you to our beloved city of Prague, which is currently becoming the capital of internal medicine. All the roads of internists from all over the world now lead to the 37th World Congress of Internal Medicine, organised by the International Society of Internal Medicine.

At this place I should present the main features of the programme, wish you a successful congress, make new contacts, present the latest clinical and scientific projects... All this is true, of course.

However I would like to focus on a few aspects of our meeting.

- First of all, it is great to be able to meet face to face again after years and to discuss in an open and friendly way the problems that are common to all of us, wherever we come from. Nothing against online meetings, but there is no substitute for face-to-face contact.

- We live in an age of emerging artificial intelligence. AI will play a very important role in medicine (including internal medicine). So we need to think carefully about where AI will be an essential helper, where it will replace human work and where, on the contrary, the role of

the creative human, the doctor or the scientist, will still be crucial.

- Perhaps, against the backdrop of Prague's historic Hundred Spires and its mysterious atmosphere, we can all take a few steps forward together and contribute to the advancement of science, research and everyday practice in the care of our patients.

- Opinions from different parts of the world, as well as data from different fields of internal medicine, are an essential enrichment of our knowledge. New preventive, diagnostic and therapeutic procedures and the progress of our medicine are born on the borders of disciplines, but also in international cooperation.

May we all have a successful congress!

And once again. Welcome to Prague for the 37th WCIM



A handwritten signature in black ink, which appears to read 'Richard Češka'. The signature is fluid and cursive, written over a horizontal line.

— Richard Češka

COMMITTEES

INTERNATIONAL SOCIETY OF INTERNAL MEDICINE (ISIM) EXECUTIVE COMMITTEE

- Prof. John Kolbe, MD
President
- Prof. Virginia Hood, MD
President Elect
- Adri Kok, MD
Past President
- Prof. Hans-Peter Kohler, MD, MACP
Secretary General
- Mr. Andres Huber
Treasurer
- Prof. Richard Češka, MD, PhD,
FACP, FEFIM
- Prof. Quazi Tarikul Islam, MD,
FCPS(BD), FRCP(Edin), MACP(USA)
- Dr. Claudia Arias, MD, FACP
- Prof. Shan-Chwen Chang, MD, PhD
- Lorenzo Diaz Salazar, MD

CONGRESS PRESIDENT WCIM 2024

- Prof. Richard Češka, MD, PhD,
FACP, FEFIM

LOCAL ORGANISING COMMITTEE

- Prof. Jiří Widimský, MD, PhD
- Prof. Michal Vrablík, MD, PhD, FEFIM
- Jan Škrha jr., MD, PhD
- Prof. Miroslav Souček, MD, PhD
- Zdeněk Monhart, MD, PhD, FEFIM
- Prof. Jan Václavík, MD, PhD,
FESC, FEFIM
- Lucie Votavová
*Executive Manager of the Czech
Society of Internal Medicine*

SUPPORT OF LOC

- Šárka Tesařová, MD
*responsible for communication
on social media*

PROGRAMME OVERVIEW

30. 10. 2024 / WEDNESDAY

CONGRESS HALL	
14:00 - 15:00	Multimorbidity (Chairs: Emma Gans, Jan Václavík)
15:00 - 16:00	Laboratory diagnostics for internists I. - cooperation with Czech Society of Clinical Biochemistry (Chairs: Tomáš Zima, Damien Gruson)
16:00 - 16:15	Coffee Break
16:15 - 17:00	Symposium 1
17:00 - 18:00	Hot Topics in Internal Medicine (Chairs: Ally Prebtani, Menno Huisman)
18:00 - 19:00	Intensive Care (Chairs: Adri Kok, Bernd W. Böttiger)
19:00 - 21:30	Opening Ceremony

31. 10. 2024 / THURSDAY

	CONGRESS HALL	SOUTH HALL 1	PANORAMA HALL	CLUB C HALL
8:30 - 9:30	Cardiology I. - Arrhythmology (Chairs: Josef Kautzner, Domenico della Rocca)			
9:30 - 10:30	Endocrinology (Chairs: Jens Bollerslev, Michal Kršek)			
10:30 - 11:00	Coffee Break			
11:00 - 12:00	Stroke (Chairs: Sándor Nardai, Jiří Widimský)	Hot Topics in the Treatment of Obesity (Chairs: Dimitri Pournaras, Martin Haluzík)		
12:00 - 13:00	Nephrology (Chairs: Virginia Hood, Christoph Wanner)	R3i (Chairs: Alberto Zambon, Michel Hermans)	Internal Medicine 1 (Chairs: Magdalena Adamiak-Kardas, Per-Henrik Groop)	
13:00 - 14:30	Symposium 2	Lunch Break	Lunch Break	
14:30 - 15:30		Symposium 4	Symposium 3	
15:30 - 16:30		Symposium 6	Symposium 5	
16:30 - 16:45		Coffee Break	Coffee Break	
16:45 - 17:45		ScreenPro FH (Chairs: G. Latkovskis, K. Rašlová)		16:30 - 18:30 1. Short oral presentations
17:45 - 18:45		IILEP - How to optimally treat patients at very high and extremely high CVD risk in 2024. IILEP 2024 recommendations	Young At Hearts (Chairs: Ieva Ruža, Jan Škrha jr.)	

1. 11. 2024 / FRIDAY

	CONGRESS HALL	SOUTH HALL 1	NORTH HALL	PANORAMA HALL		CLUB C HALL
8:30 - 9:30	Gastroenterology (Chairs: Peter Malferteiner, Milan Lukáš)					
9:30 - 10:30	Diabetes (Chairs: Manfredi Rizzo, Jan Škrha)					
10:30 - 11:00	Coffee Break					
11:00 - 12:00	Pneumology - What is new in Respiratory Diseases? (Chairs: Martina Koziar Vašáková, John Kolbe)	Laboratory Diagnostics or Internists II. - cooperation with European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) (Chairs: Mario Plebani, Etienne Cavalier)	Pharmacological and invasive strategies in hypertension - endorsed by ESH (Chairs: Thomas Weber, Jiří Widimský)			
12:00 - 13:00	ACP + ISIM + EBIM	Polyvascular Patients in Internal Medicine (Chairs: Juraj Madarič, Debora Karetová)	Pharmacological and invasive strategies in hypertension			
13:00 - 14:30	Symposium 7	Lunch Break	Lunch Break			
14:30 - 15:30				Elevated Lp(a) (Chairs: Michal Vrablík, Richard Češka)		
15:30 - 16:30				Lp(a): policies, best practices and tips to enhance acceptance (Chair: Michal Vrablík)		
16:30 - 16:45				Coffee Break		
16:45 - 17:45		Critical Appraisal of Guidelines in Internal Medicine	Rare Diseases (Chairs: Baris Akinci, Aleš Linhart)	Rheumatology (Chair: Karel Pavelka)	16:30 - 18:30	2. Short lecture presentations
17:45 - 18:45		Heart Failure (Chairs: F. Málek, Milan Luknár)	Tobacco/Nicotine use in Clinical Practice (Chairs: Peter Hajek, Eva Králíková)	Internal Medicine - WCIM Together with McMaster Course (Chairs: Roman Jaeschke, Zdeněk Monhart)		

2. 11. 2024 / SATURDAY

	SOUTH HALL 1		CLUB C HALL
9:00 - 10:00	Improving Treatment Adherence - A new Cornerstone in the Treatment of Arterial Hypertension (Chairs: Aleksander Prejbisz, Jan Václavík)	8:00 - 10:00	3. Short oral presentations
10:00 - 11:00	Intensive Care II (Chair: Michal Vrablík)		
11:00 - 12:00	Choosing Wisely (Chairs: Ivica Lazúrová, Dan Rakušan)	10:00 - 12:00	4. Short oral presentations

DETAILED PROGRAMME

30.10.2024

CONGRESS HALL

14:00 - 15:00 / Multimorbidity (Chairs: Emma Gans, Jan Václavík)

- 14:00 – A Tailored Approach to Care for Patients with Multiple Long-Term Conditions – insights from international guidelines (Emma Gans)
- 14:20 – Innovative strategies in managing drugs and polypharmacy in patients with multimorbidity (Máximo Bernabeu-Wittel)
- 14:40 – Case based learning: How to rationalize pharmacotherapy of a multimorbid senior inpatient? (Jan Václavík)

15:00 - 16:00 / Laboratory diagnostics for internists I. - cooperation with Czech Society of Clinical Biochemistry (Chairs: Tomáš Zima, Damien Gruson)

- 15:00 – Tumor markers – using in the general practice (Tomáš Zima, Drahomíra Springer)
- 15:20 – Cardiac markers (Karl Lackner)
- 15:40 – Laboratory diagnostic and monitoring the sepsis (Martin Matějovič)

16:00 - 16:15 / Coffee Break

16:15 - 17:00 / Symposium 1

17:00 - 18:00 / Hot Topics in Internal Medicine (Chairs: Ally Prebtani, Menno Huisman)

- 17:00 – Hyponatremia (Ally Prebtani)
- 17:20 – New anticoagulants in the thrombosis arena – are factor XI inhibitors moving us forward in the right direction? (Menno Huisman)
- 17:40 – Modern treatment of HLP (Peter J. Lansberg)

18:00 - 19:00 / Intensive Care (Chairs: Adri Kok, Bernd W. Böttiger)

- 18:00 – Antibiotic management and stewardship in the Intensive care unit (Adri Kok)
- 18:20 – Cardiopulmonary resuscitation in 2023 - The BIG FIVE et al. (Bernd W. Böttiger)
- 18:40 – Evaluation of Non-Variceal Gastrointestinal Bleeding in the Emergency Department (Lorenzo Díaz Salazar)

19:00 - 21:30 / Opening Ceremony

- The AI Revolution in Medicine (Behshad Behzadi)

31.10.2024

CONGRESS HALL

8:30 - 9:30 / Cardiology I. - Arrhythmology (Chairs: Josef Kautzner, Domenico della Rocca)

- 8:30 – Cardioneuroablation: a novel therapy for recurrent neurocardiogenic syncope (Piotr Kułakowski)

- 8:50 – Pulse field ablation: have we found a holy grail? (Domenico della Rocca)
- 9:10 – Catheter ablation of ventricular arrhythmias: still underused treatment modality (Josef Kautzner)

9:30 - 10:30 / Endocrinology (Chairs: Jens Bollerslev, Michal Kršek)

- 9:30 – Primary hyperparathyroidism (Jens Bollerslev)
- 9:50 – Should all patients with hypertension be screened for primary aldosteronism? New answers to an old question (Martin Reincke)
- 10:10 – Management of adrenal incidentaloma-an update (Michal Kršek)

10:30 - 11:00 / Coffee Break

11:00 - 12:00 / Stroke (Chairs: Sándor Nardai, Jiří Widimský)

- 11:00 – Hypertension and stroke (Jiří Widimský)
- 11:20 – Atrial fibrillation and stroke (Petr Widimský)
- 11:40 – Interventional treatment of acute ischemic stroke (Sándor Nardai)

12:00 - 13:00 / Nephrology (Chairs: Virginia Hood, Christoph Wanner)

- 12:00 – Preventing recurrence of kidney stones: patients need an internist's perspective (Virginia Hood)
- 12:20 – Recent progress in the treatment of diabetic kidney disease (Christoph Wanner)
- 12:40 – Emerging modes of treatment in IgA nephropathy (Vladimir Tesař)

13:00 - 14:30 / Symposium 2

SOUTH HALL 1

11:00 - 12:00 / Hot Topics in the Treatment of Obesity (Chairs: Dimitri Pournaras, Martin Haluzík)

- 11:00 – Obesity, a global threat (Ada Cuevas Marín)
- 11:20 – Pharmacological treatment of obesity: current option and future possibilities (Martin Haluzík)
- 11:50 – Bariatric surgery in the treatment of obesity: what are the options? (Dimitri Pournaras)

12:00 - 13:00 / R3i (Chairs: Alberto Zambon, Michel Hermans)

- 12:00 – What does it mean „Residual Risk“ (Michel Hermans)
- 12:30 – How to manage atherogenic/diabetic DLP (Alberto Zambon)

13:00 - 14:30 / Lunch Break

14:30 - 15:30 / Symposium 4

15:30 - 16:30 / Symposium 6

16:30 - 16:45 / Coffee Break

16:45 - 17:45 / ScreenPro FH (Chairs: G. Latkovskis, K. Rašlová)

- 16:45 – Familial hypercholesterolemia - clinical picture and treatment (Katarina Lalić)
- 17:00 – FH Homozygotes (Belma Pojskić)
- 17:15 – Croatian National Campaign on Cholesterol “Do you know your number?” (Ivan Pećin)
- 17:30 – Is it beneficial to treat hypercholesterolemia in older adults? (Miguel Angel Falasco)

17:45 - 18:45 / ILEP - How to optimally treat patients at very high and extremely high CVD risk in 2024. ILEP 2024 recommendations. (Chairs: M. Banach, I. Pećin)

- 17:45 – Upfront lipid lowering combination therapy - start early, avoid CVD events. Do we have enough data for this? What patients benefit the most? (Maciej Banach)
- 18:05 – ILEP recommendations on the role and place of bempedoic acid in lipid lowering therapy. Whether bempedoic acid should be indicated only for statin intolerance? (Ivan Pećin)
- 18:25 – Global Approaches to Managing Children with Heterozygous Familial Hypercholesterolemia (Ibadete Bytyçi)

PANORAMA HALL

12:00 - 13:00 / Internal Medicine 1 (Chairs: Magdalena Adamiak-Kardas, Per-Henrik Groop)

- 12:00 – How can the digital medicine help in better patient adherence? (Przemyslaw Kardas)
- 12:20 – What sort of aesthetic medicine complications could you see in the Emergency Department? (Magdalena Adamiak-Kardas)
- 12:40 – Is chronic kidney disease a point of no return? (Per-Henrik Groop)

13:00 - 14:30 / Lunch Break

14:30 - 15:30 / Symposium 3

15:30 - 16:30 / Symposium 5

16:30 - 16:45 / Coffee Break

17:45 - 18:45 / Young At Hearts (Chairs: Ieva Ruža, Jan Škrha jr.)

- 17:45 – Challenges in the (Women) Leadership Journey (Ieva Ruža)
- 18:05 – Second Victims (Andrea Madarasová Gecková)
- 18:25 – Ethical Challenges (Christine Sävervall)

CLUB C

16:30 - 18:30 / 1. Short oral presentations

- 16:30 – ID 114: A preliminary ultrasound bed-side method for the evaluation of the systemic vascular resistances in patients with heart failure. (Antonio Martocchia)
- 16:36 – ID 173: Endothelial markers in type 2 diabetic patients with acute decompensated heart failure: a pilot study (Jakub Jurica)
- 16:42 – ID 189: Evaluation of lipid-lowering therapy in patients with polyvascular disease based on the extent of coronary artery disease (KAMMA Registry) (Tatiana Batluk)
- 16:48 – ID 224: Nocturnal hypoxemia predicts increased mortality risk in heart failure patients, earlier and independent of first proBNP value. (Hamza Nahoui)
- 16:54 – ID 277: Prognostic prediction in very elderly patients with chronic heart failure (Adriana Costa)
- 17:00 – ID 390: The power of blood count, creatinine, and NT pro-BNP ratios in predicting Heart Failure exacerbations (J. Guilherme Gonçalves-Nobre)

- 17:06 – ID 466: Development of rivaroxaban capsules with reliable absorption in various meal regimes. (Jan Bosak)
- 17:12 – ID 522: Effectiveness of sacubitril/valsartan for the treatment of congestive heart failure in patients with atrial fibrillation (Tamar Saralidze)
- 17:18 – ID 539: The Role of NT-proBNP as a Prognostic Marker in Intensive Neurorehabilitation (Camilla Grifoni)
- 17:24 – ID 555: Baroreflex dysfunction in postural tachycardia syndrome and vasodepressor form of orthostatic intolerance (Jan Galuszka)
- 17:30 – ID 136: Prevalence of dysmagnesemia in critically ill patients & its outcomes: A prospective study (Jawahar Al Noumani)
- 17:36 – ID 396: Effectiveness of Polycythemia Vera Screening in Patients with a Hemoglobin Value of 16/16.5 gr/dl with New Diagnostic Criteria (Ugur Koca)
- 17:42 – ID 410: Influence of frailty and major neurocognitive disorders on rehabilitation success after hip fracture surgery in an Italian orthogeriatrics unit (Paolo Mazzola)
- 17:48 – ID 448: Is Risk Factor Paradox a myth? (Selvalakshmi Ravichandran)
- 17:54 – ID 529: Determinants of Falls in Patients Hospitalized in the Internal Medicine Wards (Ahmet Bahadır Ak)
- 18:00 – ID 551: Risk Factors for Falls Following Hospitalization: Insights from a Prospective Cohort of Older Patients Admitted from the Emergency Department (MARCELA ARRUDA)
- 18:06 – ID 574: Association of Nutritional Status in the Quality of Life Among Patients with Gastrointestinal Cancer Undergoing Treatment in Government Hospital (Maurice Jeanne Aguero)
- 18:12 – Additional Q&A

01.11.2024

CONGRESS HALL

8:30 - 9:30 / Gastroenterology (Chairs: Peter Malfërtheiner, Milan Lukáš)

- 8:30 – Drugs for coeliac disease (Knut Lundin)
- 8:50 – Efficacy and safety of proton pump inhibitors in clinical practice (Peter Malfërtheiner)
- 9:10 – Innovative therapy in IBD: focus on biologicals and small molecules (Milan Lukáš)

9:30 - 10:30 / Diabetes (Chairs: Manfredi Rizzo, Jan Škrha)

- 9:30 – Modern treatment of T2 diabetes (Manfredi Rizzo)
- 9:50 – New classification of diabetes (Michael Roden)
- 10:10 – Hypoglycemia in people without diabetes (Jan Škrha)

10:30 - 11:00 / Coffee Break

11:00 - 12:00 / Pneumology - What is new in Respiratory Diseases? (Chairs: Martina Koziar Vašáková, John Kolbe)

- 11:00 – Modern Management of Bronchiectasis (John Kolbe)
- 11:15 – Chronic obstructive lung diseases. Is it one or more diseases? (Vladimir Koblížek)
- 11:30 – Lung cancer screening in the Czechia and EU (Martina Koziar Vašáková)

12:00 - 13:00 / ACP + ISIM + EBIM

- 12:00 – Internal Medicine The global view (John Kolbe)
- 12:20 – Internal Medicine in the USA (Isaac O. Opole)
- 12:40 – The future of education in internal medicine (Reinold Gans)

13:00 - 14:30 / Symposium 7

SOUTH HALL 1

11:00 - 12:00 / Laboratory Diagnostics or Internists II. - cooperation with European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) (Chairs: Mario Plebani, Etienne Cavalier)

- 11:00 – Laboratory parameters of kidney diseases (Etienne Cavalier)
- 11:20 – New advanced techniques in laboratory medicine (David Friedecký)
- 11:40 – Laboratory medicine – Point of care testing (POCT) vs. laboratories (Mario Plebani)

12:00 - 13:00 / Polyvascular Patients in Internal Medicine (Chairs: Juraj Madarič, Debora Karetová)

- 12:00 – Exercise and diet (lifestyle) in patients with peripheral atherosclerosis (Lucia Mazzolai)
- 12:20 – How should we treat carotid artery stenosis? (Juraj Madarič)
- 12:40 – Abdominal aortic aneurysm (AAA) – when to screen and treat (Debora Karetová)

13:00 - 14:30 / Lunch Break

16:45 - 17:45 / Critical Appraisal of Guidelines in Internal Medicine

- 16:45 – Community Acquired Pneumonia (Oğuz A. Uyaroglu)
- 17:00 – Treatment Hyperglycemic Inpatients (Jan Škrha jr.)
- 17:15 – Acute heart failure (Zdeněk Monhart)

17:45 - 18:45 / Heart Failure (Chairs: F. Málek, Milan Luknár)

- 17:45 – From hypertension to HFpEF (Jiří Pařenica)
- 18:00 – Heart failure - increasing number of patients and forecast for the future (Jiří Jarkovský)
- 18:15 – Innovative heart failure pharmacotherapy reduces risk of sudden cardiac death (Markéta Hegarová)
- 18:30 – Right ventricular failure (Milan Luknár)

NORTH HALL

11:00 - 12:00 / Pharmacological and invasive strategies in hypertension - endorsed by ESH (Chairs: Thomas Weber, Jiří Widimský)

- 11:00 – Atherosclerotic renovascular disease (Andrzej Januszewicz)

11:20 – Renal denervation in resistant hypertension: experience from specialised centre (Thomas Weber)

11:40 – Resistant hypertension: current approaches (Jiří Widimský)

12:00 - 13:00 / Pharmacological and invasive strategies in hypertension

13:00 - 14:30 / Lunch Break

16:45 - 17:45 / Rare Diseases (Chairs: Baris Akinci, Aleš Linhart)

16:45 – Lipodystrophy (Baris Akinci)

17:05 – Rare but treatable diseases among patients diagnosed with hypertrophic Cardiomyopathy (Aleš Linhart)

17:25 – HLP as rare diseases (Richard Češka)

17:45 - 18:45 / Tobacco/Nicotine use in Clinical Practice (Chairs: Peter Hajek, Eva Králíková)

17:45 – Intervention to smokers - a standard part of medical care (online) (Ivana Croghan, Ryan Hurt)

18:05 – Nicotine: a poison or medication? (Peter Hajek)

18:25 – Basic facts about smoking in general medicine (Eva Králíková)

PANORAMA HALL

14:30 - 15:30 / Elevated Lp(a) (Chairs: M. Vrablík, R. Češka)

14:30 – Sadberk Lale Tokgözoğlu ...The global problem

14:50 – Alberto Zambon ... and CVD risk

15:10 – Peter J. Lansberg ... and therapeutic approach

15:30 - 16:30 / Lp(a): policies, best practices and tips to enhance acceptance (Chair: Michal Vrablík)

M. Banach, R. Češka, K. Čillíková , P. Lansberg,

M. Rizzo, L. Tokgozoglu, A. Zambon

16:30 - 16:45 / Coffee Break

16:45 - 17:45 / Rheumatology (Chair: Karel Pavelka)

16:45 – New strategy of management of rheumatoid arthritis (Eugene J. Kucharz)

17:05 – Update of Therapy of psoriatic arthritis (Karel Pavelka)

17:20 – Addressing the diagnosis and management of rheumatic immune-related adverse events resulting from checkpoint inhibitors (Ladislav Šenolt)

17:35 – Interstitial lung diseases associated with connective tissue diseases – how to manage patients at risk (Michal Tomčík)

17:45 - 18:45 / Internal Medicine - WCIM Together with McMaster Course (Chairs: Roman Jaeschke, Zdeněk Monhart)

17:45 – Sepsis - what is old, what is new, what is crucial to know (Roman Jaeschke)

18:05 – Intravenous fluid management in acutely ill patients (Martin Matějovič)

18:25 – The differences in treating very old patients on intensive care (Wojciech Szczeklik)

CLUB C

16:30 - 18:30 / 2. Short lecture presentations

- 16:30 – ID 105: Cardiovascular risk factors in Czech population aged 25–64 with respect to diabetes (Juraj Michalec)
- 16:36 – ID 149: UTILIZATION OF ROTATIONAL THROMBOELASTOMETRY FOR HEMOSTASIS EVALUATION IN PATIENTS WITH PSORIASIS: A PILOT PROSPECTIVE STUDY (Martin Jozef Pěč)
- 16:42 – ID 395: Cefepime versus Piperacillin-Tazobactam in Empirical Treatment for Hospitalized Patients with Bacterial Infection: A Systematic Review and Meta-Analysis (Giovanna Leandro)
- 16:48 – ID 412: Acupuncture for the Treatment of Chronic Itchiness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Giovanna Leandro)
- 16:54 – ID 427: An Updated Meta-Analysis of Randomized Controlled Trials of DAPT Versus Aspirin in Patients with Stroke or Transient Ischemic Attack (Muhammad Basil Raza)
- 17:00 – ID 564: Monocyte Distribution Width as a mortality indicator in septic patients (DIMITRIOS Theodoridis)
- 17:06 – ID 451: Artificial intelligence driven lifestyle change positively impacts type II diabetes and prediabetes. (Niall Colwell)
- 17:12 – ID 65: AI vs. Human: Evaluating the Efficacy of AI-Generated Patient Information Leaflets in Healthcare Communication (Manisha Coran)
- 17:18 – ID 374: The metabolomic signature of salt intake (Jonas Wuopio)
- 17:24 – ID 494: Reducing hyperuricemic events with SGLT2 inhibitors: an updated systematic review and meta-analysis with meta-regression (Hamlet Ghukasyan)
- 17:30 – ID 86: Turkish validity and reliability of Burnout Syndrome Assessment Scale for Nurses Working in intensive care units (Yağmur Dağ)
- 17:36 – ID 126: Retrospective evaluation of suicide attempt cases admitted to the emergency internal medicine unit: Tertiary hospital experience (Merve Guzel Dirim)
- 17:42 – ID 339: TTM for different ROSC timing in OHCA patients (Ming-hao Chen)
- 17:48 – ID 409: Prophylaxis of Ventilator-Associated Pneumonia Using β -Lactam in Patients with Brain Injury: A Systematic Review, Meta-Analysis and Trial Sequential Analysis (Arthur R. Monteiro)
- 17:54 – ID 71: Efficacy and safety of subcutaneous compared to intravenous monoclonal antibodies for inflammatory bowel disease - A meta-analysis (Nouran Alwisi)
- 18:00 – ID 302: relationship between helicobacter pylori infection, age, and gender with incidences of gastric polyp in makassar, indonesia. (Rini Bachtiar)
- 18:06 – ID 400: Fistulous walled off necrosis: a case presentation (Merve Feyza Demir Gürdal)
- 18:12 – Additional Q&A

02.11.2024

SOUTH HALL 1

9:00 - 10:00 / Improving Treatment Adherence - A new Cornerstone in the Treatment of Arterial Hypertension (Chairs: Aleksander Prejbisz, Jan Václavík)

- 9:00 – How to manage non-adherence in everyday practice? (Michel Burnier)
- 9:20 – A practical approach to assessment of nonadherence to antihypertensive treatment (Jan Václavík)
- 9:40 – Pharmacological and non-pharmacological treatment of hypertension - how to effectively convince the patient to comply? (Aleksander Prejbisz)

10:00 - 11:00 / Intensive Care II (Chair: Michal Vrablík)

- 10:00 – Should prediabetic patients with hypercholesterolemia be treated with statins? (Miguel Angel Falasco)
- 10:20 – Management of Chest Pain in the Emergency Department (Lorenzo Díaz Salazar)
- 10:40 – Does a multidisciplinary team involving internists specialized in hypertension and obstetric medicine improve pregnancy outcomes? (Federica Piani)

11:00 - 12:00 / Choosing Wisely (Chairs: Ivica Lazúrová, Dan Rakušan)

- 11:00 – Choosing Wisely in clinical practice: Embracing critical thinking (Ludovico Furlan)
- 11:20 – Choosing wisely in endocrinology - what should we reduce? (Ivica Lazúrová)
- 11:40 – Wise cancer screening and pharmacotherapy in gastroenterology (Jiří Cyraný)

CLUB C

8:00 - 12:00 / 3. Short oral presentations

- 8:00 – ID 174: Predictors of Mortality in Hospitalized HIV/AIDS Patients at Tertiary Hospital in Indonesia. (Rentha Monica Simamora)
- 8:06 – ID 274: Post-transplant diabetes and diabetic foot - a challenge for multidisciplinary cooperation (Tomas Paduch)
- 8:12 – ID 283: Impact of acute hospitalization on long-term pharmacotherapy in multimorbid patients – retrospective multicenter study (Zdenek Lys)
- 8:18 – ID 344: Provision of medical Same Day Emergency Care services within the UK (Cat Atkin)
- 8:24 – ID 397: Massive upper gastrointestinal bleeding: The impact of a prompt approach of the critic patient (Isabel Borges da Ponte)
- 8:30 – ID 414: The Efficiency of Oseltamivir in Reducing Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis (Giovanna Leandro)
- 8:36 – ID 487: Post Dengue Fatigue Syndrome (PDFS) : A study of 100 patients in a Tertiary Care Hospital of Bangladesh (Tazin Afrose Shah)
- 8:42 – ID 488: Disparities in Chronic Care Management between Males and Females: Study of 500 patients in private hospital of Dhaka, Bangladesh (Tazin Afrose Shah)
- 8:48 – ID 497: Are We Over-Reliant On Hba1c? A Three-Year Case Of Diabetes Mellitus With Masked Hereditary Spherocytosis (Aslı Kisacik Duru)

- 8:54 – ID 528: Relationship between health literacy levels and chronic complications of diabetes mellitus in diabetic patients (Merve Feyza Demir Gürdal)
- 9:00 – ID 25: Evaluation of vitamin D status among the doctors of Bangladesh - A multicenter cross sectional study (Quazi Tarikul Islam)
- 9:06 – ID 182: A case study of melatonin supplementation and continuous glucose monitoring on glycemic control, glucose variability, and sleep quality (Masab Mansoor)
- 9:12 – ID 314: Prediction of significant fibrosis in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease using machine learning (Chamila Mettananda)
- 9:18 – ID 408: Thyroid carcinoma in surgery-treated hyperthyroid patients: Experience of a tertiary care public hospital in Colombia, 2012-2023 (César Alfonso Gómez Fontalvo)
- 9:24 – Additional Q&A

9:50 - 10:00 / Break

10:00 - 12:00 / 4. Short oral presentations

- 10:00 – ID 97: Machine Learning-Based Mortality Prediction Model for Patients with Chronic Hepatitis C Infection: Exploratory Study (Abdullah Al Alawi)
- 10:06 – ID 151: Characterisation of non-cirrhotic MAFLD-related hepatocellular carcinoma (Liang Qiao)
- 10:12 – ID 347: Ursodeoxycolic acid has no effect on survival in MASLD (Ozge Ucuz)
- 10:18 – ID 239: Comorbidity of patients with albuminuria – AURA registry data (Alexander Arutyunov)
- 10:24 – ID 332: Personalized management of patients with diabetic kidney disease with the focus on determining approaches to diagnostic and treatment (Oksana Borzykh)
- 10:30 – ID 411: Chronic Kidney Disease in Young Adult: A Case Report (Alexandra Nascimento)
- 10:36 – ID 495: To the point of bloodshed... or an inventive solution of AIHA-induced acute kidney injury (Kristína Liachovická)
- 10:42 – ID 554: Pneumonia Severity Index Score as a predictor of community acquired pneumonia mortality (Inês Peneda Ferreira)
- 10:48 – ID 558: CURB-65 score as a predictor of community acquired pneumonia mortality (Inês Filipa Silva)
- 10:54 – ID 183: Allopurinol Prescription Patterns among Patients Attending Primary Health Care Centers in Qatar: A Retrospective Cross-Sectional Study (Hussein Chalhoub)
- 11:00 – ID 278: Diagnosis of previously unverified Crohn's disease in patients with rheumatic diseases based on the level of fecal calprotectin (Elizaveta Vasilenko)
- 11:06 – ID 280: Prevalence of HLA-B27 and HLA-Cw6 alleles in
- 11:12 – ID 281: Patterns and clinico-demographic characteristics of vasculitis: experience of a referral rheumatology centre of Bangladesh (Md Mallik Mallik)
- 11:18 – ID 404: Efficacy and Effects of Krill Oil for Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (Arthur R. Monteiro)
- 11:24 – ID 468: Therapeutic plasma exchange in patients with rheumatic diseases: single centre experience. (Alina Agule)
- 11:30 – ID 481: Do fibromyalgia and neuropathy play role in biologic switch in sPA and RA? (Hasan Ozdek Sayilir)
- 11:36 – Additional Q&A

USEFUL INFORMATION

CONGRESS VENUE

Prague Congress Centre
5. května 1640/65
140 21 Prague 4
Czech Republic

praguecc.cz

FREE WI-FI IS AVAILABLE IN THE WHOLE EVENT AREA

SSID – WCIM2024
Password – Prague2024

REGISTRATION

Only registered participants will be admitted to the scientific section, exhibition, poster section and courses.

Please check your congress materials upon registration. Late claims cannot be accepted.

Opening Hours of Registration, Cash, Information

30.10. 12:00-20:00

31.10. 8:00-19:00

1.11. 8:00-19:00

2.11. 8:30-13:00

INFORMATION FOR SPEAKERS

Your presentation must be submitted to the “Speakers Ready Room” at least 30 minutes before the beginning of your session. A technician is available in every session room to provide assistance when needed. Due to the online presentation system, all speakers are kindly requested to use provided PC onsite. Please be present in the session room 15 minutes prior to the start of your session and follow the instructions from the Chairs and/or technician.

Opening Hours of Speakers’ Ready Room

30.10. 12:00-20:30

31.10. 7:30-18:45

1.11. 7:30-18:45

2.11. 8:00-13:00

Lp(a) Testing

We would like to inform you that Lp(a) testing will be available on **October 31st** and **November 1st**. The testing will take place in the **South Meeting Room 225**, on the **2nd floor**, from **9:00 AM to 5:00 PM**.

CME ACCREDITATION

The 37th World Congress of internal medicine 2024 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 18.5 European CME credits (ECMEC®s).

PARTNERS AND EXHIBITORS

WE THANK THE FOLLOWING
PARTNERS FOR THEIR SUPPORT!

GOLD PARTNER



EXHIBITORS



MEDIA PARTNERS

acta medicinae

OTHER PARTNERS





prague
city tourism



EXHIBITION PLAN

2nd floor



Internal Medicine Corner

- | | |
|--------|----------|
| 1 CSIM | 4 ACP |
| 2 ISIM | 5 EFIM |
| 3 TSIM | 6 MIRCIM |

Exhibitors

- | | |
|-------------------|-------------------------------|
| 7 AMBOSS | 10 Wisepress Medical Bookshop |
| 8 Beckman Coulter | 11 Zentiva |
| 9 Wörwag Pharma | |

INDUSTRY SYMPOSIA

30. 10. 2024

SYMPOSIUM 1 - LILLY



Redefining T2D and Obesity Management with GIP/GLP-1 receptor agonist

Time:

16:15 - 17:00

Hall:

Congress Hall

Chair: M. Haluzík

- **M. Haluzík** (Prague, Czech Republic)
 - The Need for proactive, comprehensive treatment of T2D and Obesity
- **T. Klupa** (Kraków, Poland)
 - Targeting Adiposity as a Root Cause for T2D and Obesity
- **L. N. R. Bondugulapati** (Abu Dhabi, UAE)
 - New Horizons in Obesity Care
- **T. Klupa (Kraków, Poland)**
 - Incretin co-agonists in the Treatment of T2D

Panel Discussion

31. 10. 2024

SYMPOSIUM 2 - ZENTIVA



Treatment of cardiovascular continuum 2024: focus on novel opportunities

Time:

13:00 - 14:30

Hall:

Congress Hall

Chair: R. Češka

- **L. Tokgozoğlu** (Ankara, Turkey)
 - How to get to LDL-C goal in the multimorbid patient?
- **A. Zambon** (Padova, Italy)
 - Beyond the usual suspects: TG-rich lipoproteins and Lp(a)
- **K. Narkiewicz** (Gdansk, Poland)
 - The silent killers: Advanced strategies for hypertension and obesity management

SYMPOSIUM 3 - DIGITAL MEDICINE

Time:
14:30-15:30

Hall:
Panorama Hall

- **I. Said Criado** (Pontevedra, Spain)
- New Skills to address Digital Medicine
- **M. Prázný** (Prague, Czech Republic)
- Digital diabetology: fiction or reality?
- **J. Škrha jr.** (Prague, Czech Republic)
- Can AI help in the postgraduate education and research?

SYMPOSIUM 4 - WÖRWAG PHARMA

The many faces of B12-deficiency and necessity of multidisciplinary management



Time:
14:30 - 15:30

Hall:
South Hall 1

- **R. Češka** (Prague, Czech Republic)
- Optimizing Patient Care: Strategies for Managing Vitamin B12 Deficiency in Internal Medicine
- **R. Obeid** (Hamburg, Germany)
- Practical Guidance for Diagnosing and Treating Vitamin B12
- Deficiency: Results of an International and Multidisciplinary B12 Consensus Conference
- **B. Hooshmand** (Tutzing, Germany)
- Vitamin B12 in Neurology: A Clinical Approach

SYMPOSIUM 5 - SANOFI

Comprehensive management of post ACS patients
– how to improve and optimize secondary prevention?



Time:
15:30 - 16:30

Hall:
Panorama Hall

Chair: R. Češka

- **A. Linhart** (Prague, Czech Republic)
- Dyslipidemia - an underappreciated risk factor in the context of a high-risk country
- **M. Vrablík** (Prague, Czech Republic)
- Fail no more. Lipid goals at our hands.
- **M. Kaluzna-Oleksy** (Poznan, Poland) - Complex ACS management - the place of lipid lowering therapy and rehabilitation – learnings from MACAMIS program in Poland - ACS forum like an experience exchange platform

SYMPOSIUM 6 - ISIM



Time:
15:30 - 16:30

Hall:
South Hall 1

- **C. Arias** (Santo Domingo, Dominican Republic) - Monkeypox
- **Q. T. Islam** (Dhaka, Bangladesh) - Emergencies in Dengue Syndrome
- **A. C. Cejudo** (Mexico City, Mexico) - Inflammatory process and the risk factors for cardiovascular diseases
- **E. Topinková** (Prague, Czech Republic) - Geriatrics

1. 11. 2024

SYMPOSIUM 7 - AMGEN



Time:
13:00 - 14:30

Hall:
Congress Hall

Chair: R. Češka

- **R. Češka** (Prague, Czech Republic) - Introduction
- **L. Tokgözoğlu** (Ankara, Turkey) - CV risk reduction with lipid lowering: When and how?
- **M. Vrablík** (Prague, Czech Republic) - The Power of Low LDL-C: Who Benefits Most and How Low is Enough
- **A. Zambon** (Padova, Italy) - From research to clinical settings: PCSK9i Real Life Experience in Europe

✓ Jediné hypolipidemikum ve vaší ambulanci
s dávkováním **2x ročně**^{1,2,*}

✓ Efektivní a dlouhodobé snížení LDL-C
o **50-55 %**¹

✓ Příznivý bezpečnostní profil¹



*Po počáteční dávce je další dávka za 3 měsíce a další vždy po 6 měsících.

Pro více informací o LEQVIO® naskenujte QR kód:



▼ Tento léčivý přípravek podléhá dalšímu sledování. To umožní rychlé získání nových informací o bezpečnosti. Žádáme zdravotnické pracovníky, aby hlásili jakákoli podezření na nežádoucí účinky. Podrobnosti o hlášení nežádoucích účinků viz SPC bod 4.8.

Zkrácená informace o přípravku LEQVIO 284 mg injekční roztok v předplněné injekční stříkačce

Složení: Jedna předplněná injekční stříkačka obsahuje inklisiranum natrium odpovídající inklisiranum 284 mg v 1,5 ml roztoku. **Indikace:** Přípravek Leqvio je indikován u dospělých s primární hypercholesterolemii (heterozygotní familiární a nefamiliární) nebo smíšenou dyslipidemií jako doplněk k dietním opatřením; v kombinaci se statinem nebo statinem v kombinaci s jinými přípravky snižujícími hladinu lipidů u pacientů neschopných dosáhnout cílů pro LDL-C při maximální tolerované dávce statinu, nebo samostatně nebo v kombinaci s jinými přípravky snižujícími hladinu lipidů u pacientů typických nesnášenlivostí statinu nebo u nichž je statin kontraindikován. **Dávkování:** Doporučená dávka je 284 mg inklisiranu podávaného jako jednorázová subkutánní injekce: počáteční dávka, další po 3 měsících a poté každých 6 měsíců. Pokud je plánovaná dávka opožděna o méně než 3 měsíce, má být inklisiran podán a dávkování má pokračovat podle pacientova původního schématu. Pokud je plánovaná dávka opožděna o více než 3 měsíce, má být zahájen nový dávkovací režim – má být podána počáteční dávka inklisiranu, další po 3 měsících a poté každých 6 měsíců. Inklisiran lze podávat okamžitě po poslední dávce monoklonální protilátky inhibující PCSK9. Pro udržení snížení LDL-C se doporučuje, aby byl inklisiran podán do 2 týdnů po poslední dávce monoklonální protilátky inhibující PCSK9. **Kontraindikace:** Hypersenzitivita na léčivou látku nebo na kteroukoli pomocnou látku.

Zvláštní upozornění/varování: Účinek hemodialýzy na farmakokinetiku inklisiranu nebyl studován. Vzhledem k tomu, že inklisiran je vylučován ledvinami, nemá se hemodialýza provádět po dobu nejméně 72 hodin od podání inklisiranu. **Interakce:** Inklisiran není substrátem pro běžné transportéry léčiv, a protože nebyly provedeny studie *in vitro*, nepředpokládá se, že bude substrátem pro cytochrom P450. Inklisiran není inhibitorem nebo induktorem enzymů cytochromu P450 nebo běžných transportérů léčiv. Proto se neobeckává, že by inklisiran měl klinicky významné interakce s jinými léčivými přípravky. Na základě omezených dostupných údajů nejsou obečkovány klinicky významné interakce s atorvastatinem, rosuvastatinem nebo jinými statiny. **Těhotenství a kojení:** Údaje o podávání inklisiranu těhotným ženám jsou omezené nebo nejsou k dispozici. Podávání inklisiranu v těhotenství se z preventivních důvodů nedoporučuje. Není známo, zda se inklisiran vylučuje do lidského mateřského mléka. Riziko pro kojené novorozence/děti nelze vyloučit. **Nežádoucí účinky:** Časté: Reakce v místě vpichu. **Podmínky uchovací:** Chraňte před mrazem. **Dostupné lékové formy / velikosti balení:** Předplněná injekční stříkačka s ochranným pouzdem jehly; 1,5 ml roztoku v předplněné injekční stříkačce (sklo třídy I) s pistovou zátkou (brombutyl, fluorotekem potažená pryž) s jehlou, pevným krytem jehly a s ochranným pouzdem jehly. Velikost balení jedna předplněná injekční stříkačka s ochranným pouzdem jehly. **Poznámka:** Dříve než lék předepíšete, přečtěte si pečlivě úplnou informaci o přípravku. **Reg. č.:** EU/1/20/1494/002 **Datum registrace:** 8.12.2020. **Datum poslední revize textu SPC:** 24.03.2022. **Držitel rozhodnutí o registraci:** Novartis Europharm Limited, Vista Building, Elm Park, Merrion Road, Dublin 4, Irsko. **Výdej přípravku je vázán na lékařský předpis, přípravek je hrazen z prostředků veřejného zdravotního pojištění.**

Reference: 1. SPC Leqvio 284 mg injekční roztok v předplněné injekční stříkačce, datum poslední revize 24.3.2022. 2. SÚKL. www.sukl.cz. 3. Wright R.S., Raal F.J., Koenig W., Landmesser U., Leiter L.A., Vikarunnessa S., et al.: Inkisiran administration potentially and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. *Cardiovasc Res.* 2024;09:109.

LEQVIO a logo LEQVIO jsou registrované ochranné známky společnosti Novartis AG. Licencováno od Aplyon Pharmaceuticals, Inc.



Invitation to the Symposia organized by Zentiva.

37th WCIM 2024 Prague

October 31st , 2024 13:00 – 14:30



Prague Congress Centre

5. května 1640/65

140 21 Prague 4

Czech Republic

Treatment of cardiovascular continuum 2024: focus on novel opportunities.

Chairman: Prof. Richard Češka, MD, PhD, FEFIM, FACP



How to get to LDL-C goal in the multimorbid patients?

Prof. Lale Tokgözoğlu MD, FACC, FESC (Ankara, Turkey)

Beyond the usual suspects: TG-rich lipoproteins and Lp(a)

Prof. Alberto Zambon MD, PhD, FAHA (Padova, Italy)

The silent killers: Advanced strategies for hypertension and obesity management


Prof. Krzysztof Narkiewicz, MD, PhD (Gdansk, Poland)

Discussion

ZENTIVA

FLOORPLANS

Ground floor



1st floor



2nd floor

